ALEXANDRIA REAL ESTATE EQUITIES, INC. Q2 FY2024 earnings call

• Recognized solid second quarter operating and financial performance despite market uncertainties.
• Released the corporate responsibility report in June 2024, highlighting operational excellence across the Labspace platform.
• Secured 100% renewable energy for 100% of paid accounts in the Greater Boston cluster market.
• Focused on refining the Labspace platform, leveraging first mover advantage in top life science clusters.
• Continues to develop and redevelop high-quality mega campuses, reducing non-mega campus pipeline and selling non-core assets.
• Strong tenant relationships, including with Lilly, demonstrate brand loyalty.
• Fortress balance sheet with significant liquidity and deep life science expertise.
• Delivered 284,982 square feet in Q2 2024, with annual incremental NOI of $16 million, and development/redevelopment leasing of ~341,000 square feet.

The company's segment performance includes various tenant segments by ARR: biomedical and government institutions (10% of ARR), private biotech companies (10% of ARR), pre-commercial public biotech companies (9% of ARR), commercial stage biopharma (17% of ARR), large multinational pharmaceutical companies (20% of ARR), and life science product, service and device tenant segment (21% of ARR). Additionally, 74% of ARR comes from mega campuses, 53% of ARR is from investment grade or big cap companies, and 96% of leases have contractual rental rate increases.

• FFO per share diluted as adjusted for 2024 is reiterated at the midpoint of $9.47, up 5.6% from prior year.
• Same property NOI growth midpoint for full year is 1.5% to 4% on a cash basis.
• Disposition strategy progress with $912 million of completed and pending dispositions under negotiation, 59% of the midpoint of $1.55 billion guidance.
• Plan to pause future issuances under the ATM program at least for the next quarter.
• Updated EPS guidance for 2024 is $2.98 to $3.10.

• Market uncertainties due to soaring U.S. debt and government spending problems.
• Supply issues in some submarkets, particularly South San Francisco, with oversupply and muted demand post-COVID rocketship.
• Competition from inexperienced developers in tertiary markets with failed projects.
• Potential impact of macroeconomic factors like debt to GDP ratio on the overall economic environment.

Q: Farrell Granath asked about the repositioning of Alexandria Technology Square mega campus and LOIs.

A: Marc Binda responded that the lease percentage on the development pipeline changed due to adding more square feet to a project at 311 Arsenal, not a surprise.

Q: Anthony Paolone inquired about cap rates on pending sales and property values.

A: Peter Moglia stated that cap rates on good quality assets are in line with commentary, and non-core assets have different cap rates.

Q: Michael Griffin asked about leasing term decline and development pipeline pushback.

A: Peter Moglia and Marc Binda explained it was due to early-stage companies signing shorter leases and a project in South San Francisco being pushed to 2026 with ongoing activities.

Q: Richard Anderson questioned about disposition funding and impairments.

A: Joel Marcus and Peter Moglia discussed that disposing non-core assets is part of refocusing on mega campuses for long-term growth.

Q: Wesley Golladay asked about non-mega campus development potential and ground lease extensions.

A: Peter Moglia and Marc Binda responded that non-mega campus development potential is part of the disposition strategy and Tech Square ground lease extension was a strategic move.

Q: Michael Carroll asked about leasing activity from early-stage biotech and supply outlook.

A: Peter Moglia and Hallie Kuhn explained that there's a barbell of early-stage and large pharma activity, and supply is progressing as expected.

Q: Vikram Malhotra inquired about near-term inflection and repositioning impact.

A: Joel Marcus provided a detailed response on market cycles and repositioning impact, and Marc Binda discussed repositioning examples like Tech Square 200.

Q: James Kammert asked about leasing activity reconciliation.

A: Marc Binda explained a project in San Diego had additional term added, causing a shift in leasing square footage.

Q: Peter Abramowitz asked about leasing spreads and larger tenant activity.

A: Joel Marcus and Hallie Kuhn commented on leasing spreads being lumpy and larger tenant activity tied to IPO market opening and clinical trial milestones.

Q: Dylan Burzinski asked about retention rates and new supply impact.

A: Marc Binda and Joel Marcus explained retention isn't significantly down when normalizing for large tenant moves, and tenants don't move for small rent differences.

Q: Omotayo Okusanya asked about Boston market rents and mark-to-market.

A: Marc Binda and Peter Moglia stated in-place mark-to-market is 12%, and Boston rents are above pre-pandemic levels despite coming off peaks.